Wednesday, October 16, 2019
News
NEWS HOME
»
PRN INDIA
Menarini Ricerche at the ASCO Annual Meeting 2019 With Three Different Projects in Oncology
  SocialTwist Tell-a-Friend  
   

POMEZIA, Italy, May 23, 2019 /PRNewswire/ -- Menarini Ricerche will present three different projects related to the compounds in clinical development SEL24/MEN1703, MEN1611 and MEN1309/OBT076 at the ASCO Annual Meeting 2019 in Chicago.

Menarini Ricerche Logo (PRNewsfoto/Menarini Ricerche S.p.A)

During the poster session "Breast Cancer – Metastatic" on June 2nd 2019, 08:00AM- 11:00AM, the poster "B-PRECISE-01 Study: a phase Ib trial of MEN1611, a PI3K Inhibitor, combined with trastuzumab ± fulvestrant for the treatment of HER2-positive advanced or metastatic breast cancer" will be presented.

MEN1611 is a potent, selective class I inhibitor of PI3K, a key enzyme in the transduction of various extracellular growth factor signals essential for cell survival and apoptosis. This poster will report the study design of the Phase Ib B-PRECISE-01 (dose escalation and cohort expansion phases). This study is currently ongoing in Europe, with the objective to select the recommended phase 2 dose and preliminary clinical activity of MEN1611 in combination with trastuzumab +/- fulvestrant (NCT03767335). The correlation of clinical end-points with PIK3CA mutations and other relevant cancer genes mutational status will be also analyzed during the trial.

During the poster session "Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant" on June 3rd 2019, 08:00AM- 11:00AM, the poster "CLI24-001: First-in-human study of SEL24/MEN1703, an oral dual PIM/FLT3 kinase inhibitor, in patients with acute myeloid leukemia" will be presented.

This poster will report the study design of the FIH clinical trial DIAMOND-01 of SEL24/MEN1703 in patients with newly diagnosed Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia and Primary Refractory Acute Myeloid Leukemia and no available therapeutic options (NCT03008187). The main aim of the study, conducted in the US, is the identification of the recommended phase 2 dose. Menarini Ricerche is eager to present this study which is the first trial testing a dual PIM/FLT3 inhibitor in AML regardless of FLT3 mutational status, and with a potential to overcome FLT3 inhibitor resistance.

A third abstract reporting the results from a retrospective evaluation of CD205 expression on tissue samples collected from patients diagnosed with triple negative breast carcinomas, pancreatic adenocarcinomas and bladder urothelial carcinomas will be disclosed by ASCO as e-publication (abstract number for publication e14726). CD205 is the target antigen of MEN1309/OBT076, a humanized IgG1 antibody against CD205, conjugated through a cleavable linker to DM4. MEN1309/OBT076 is currently in phase I in Europe (CD205-SHUTTLE study), recruiting patients affected by solid tumors and Non-Hodgkin Lymphoma (NCT03403725). A second phase I trial conducted by OBT is imminent in the US.

The results of this investigation on the target distribution will be important in supporting the clinical investigation of MEN1309/OBT076 in these tumor types.

The contribution of Menarini Ricerche to ASCO with data related to three compounds in our current pipeline, demonstrates the commitment of Menarini to oncology, and to developing new drugs for patients with difficult to treat cancers and poor prognosis.

About Menarini

Menarini Group is an Italian pharmaceutical company with a turnover of 3.67 billion Euro and more than 17,600 employees. The Menarini Group has always pursued two strategic objectives: research and internationalization, and has a strong commitment to oncology research and development. As part of such commitment to oncology, Menarini, is developing four investigational new oncological drugs. Two of them are biologics, one is the monoclonal antibody anti-CD157 MEN1112/OBT357, and the other is a toxin-conjugated, anti-CD205 antibody MEN1309/OBT076. Other two are small molecules, the dual PIM and FLT3 kinase inhibitor SEL24/MEN1703, and the PI3K inhibitor MEN1611, in clinical development for the treatment of a variety of hematological and/or solid tumors. In addition, Menarini has recently signed a licensing agreement for a small molecule, an inhibitor of class I, II, and IV histone deacetylase, Pracinostat, for the treatment of patients with hematological diseases. Menarini is active commercially in the most important therapeutic areas with products for cardiology, gastroenterology, pneumology, infectious diseases, diabetology, inflammation, and analgesia.

With 16 production sites and 7 Research and Development centers, the Menarini Group has a strong presence throughout Europe and Asia, Africa, Central and South America. Menarini's products are available in 136 countries worldwide.

For further information please visit www.menarini.com

Logo: http://mma.prnewswire.com/media/520214/Menarini_Ricerche_Logo.jpg  


 

More News by PR Newswire India

LifeNet Health brings first clinically proven allograft-based biologic wound therapy to India

The Smart Contract Security Alliance Announces Founding Council

Patrick Imbardelli Elected to YPO Board of Directors

World Intellectual Property Indicators: Filings for Patents, Trademarks, Industrial Designs Reach Record Heights in 2018

Saudi Joy Forum 19, A Success For The Region And World

AIC Named North American Distributor Of Organic Rice, Organic Brown Rice And Organic Pumpkin Seed Proteins

WISPA Members Vote Cambium Networks Manufacturer of the Year

IMI and GustoMSC Sign Jack-up Design License Agreement

New Report: Laundry Releases Trillions of Plastic Microfibers Into the Ocean

FOX Bet Strikes Multiyear Deal With Major League Baseball

OhmniLabs Showcases Latest Telerobotics Innovations At CEATEC 2019

Airspan - Breaking Down the Barriers to Entry With the New Mimosa Connectorized A5x Access Point

TMP Worldwide Acquires UK-Based Social Media Leader Carve

CleverTap Completes $35 Million Series C Funding to Drive Global Growth

Charles Manning, Founder and CEO, Kochava, joins Forbes Technology Council

10th Foundation Day Celebrations Start at Shoolini University

Tourcom LLC, Holding Company of Tourcom Blockchain, Signs Strategic Investment Agreement through Equity Acquisition of Travel Information Sharing Service 'Wishbeen'

WorkBoard Announces Deeper Jira Integration to Bring Team OKRs into Developers' Jira Experience

Cision Announces Exclusive Platinum Sponsorship For PRSA 2019 International Conference

Systech Expands Market-Leading Brand Protection Solution for Improved Supply Chain Visibility

Artificial intelligence is transforming health care across Asia, fuelled by innovative public-private sector R&D and a focus on domestic health-care burdens

Sirius Design Group Generates $1.2m Revenue in 4 Years Helping Clients With Digital Real Estate

Dynata Launches New Platform to Transform the Future of Insights and Marketing

S BLOCK Co-Hosts WBF 2019 Indonesia Technology Conference, Creates DAO Super Community

TUV Rheinland Enables LoRaWAN(R) Certification in India

Tukatech Releases TUKAcad for Subscription in Native Languages for 4.38 Billion People

IDFC FIRST Bank and Sodexo Partner to Introduce Digital Meal Benefit Solution for Corporate Employees

Whale Cloud Unveils 5G Operation Map at India Mobile Congress 2019

LyondellBasell Announces Construction of New Small-Scale Molecular Recycling Facility

Celemics Expedites Target Enrichment NGS Data Insights by Partnering With BlueBee on a Global Genomics Data Solution

ZTE launches industry-first 5G+VDSL2 hybrid home gateway

OYO's HR Team Saved 75% At-risk Employees Using inFeedo's Engagement bot, Amber

Ameyo Integrates With Freshworks to Simplify Customer Journey

Nuclear Days 2019 - French Nuclear Industry to Intensify its Operations in Indian Market

Happiest Minds Wins 2019 Red Herring Top 100 Asia Award

The Spielwarenmesse Reveals the Trends for 2020

Xinhua Silk Road: SAIC Motor gains momentum in India with 31,000 orders received by September

CreditVidya Wins the Prestigious 2019 Red Herring Top 100 Asia Award

GCW Global Customised Wealth Announces New Partner: Tim Babich

GTPL Hathway's Consolidated H1 FY20 PAT at â‚ą 580 Million, up by 102%

'Where Will Man Take Us?' by Atul Jalan has been Certified a National Bestseller by Penguin Random House India

Tejas Networks Launches World's Largest Disaggregated Packet-optical Switch at India Mobile Congress 2019

Building on Local Momentum: Malaysia's Greater Petaling Joins City Cancer Challenge

Shanghai International Money Fair - one of China's largest financial fairs will be held in December

Europe's Most Trusted Crypto And Precious Metal Companies Partner To Create Gold Token Secured By Bitcoin Network

RGE Commits US$200 Million to Next-Generation Textile Fibre Innovation and Technology

Medisanté Earns Acclaim from Frost & Sullivan for Ensuring Better Care Outcomes while Reducing Costs

INSIDE INFORMATION: BW LPG Contemplated Sale of Shares

School House Crafts Multi-Sensory Journey of Discovery and Re-collection for La Mer Campaign Exhibition

Vevue Partners with CBX Exchange for Initial Auction Offering

Frost & Sullivan Recognizes Pepco Holdings and Carlsbad Municipal Water District with Excellence in Resourcefulness Awards at Itron Utility Week

His Holiness The Dalai Lama Awarded Honorary Doctorate by Chitkara University

Surplus Keslow Cinematography Gear Up For Auction

Libyan Investment Authority Loses Claim in the UK Court of Appeal - London

Artificial Intelligence for Risk Management Process by MovingNow

Maruti Suzuki Arena Devils Circuit Season 2019-20 Draws Over 6K Runners in Hyderabad

Quectel Achieves Industry's First 5G Data Call over 5G mmWave Module

Artprice by Artmarket: The Gagosian's Grand Projects for the Late Simon HantaĂŻ (1922-2008)

Ryan International Group of Schools Receive India's Most Respected Brand Award 2019

JD Institute Of Fashion Technology, South Announced its New Domain

VeChain Is Leading Co-sponsor of GDST Seafood Trackathons

The World's Largest Automakers, Along with MOBI, Announce a Joint Proof of Concept for the First Vehicle Identity on Blockchain

Indiannica Learning Announces the Launch of Indiannica Quiz League

Third Annual Convocation Ceremony Will be Celebrated in Apex Professional University

An Encounter of Two Icons: Tic Tac® Meets Coca-Cola®

Birlasoft to Accelerate Invacare's Business Transformation Journey Signs US$ 240 mn, Multi-year Deal, to Provide Complete IT-as-a-Service (ITaaS)

Bali Zoo Celebrated Tumpek Kandang Ritual for all its Resident Faunas

Nitin Mantri Becomes ICCO President

DMCC Awarded 'Global Free Zone of the Year' for a Record Fifth Consecutive Year

Apex Professional University Signed MoU with Life Science Sector Skill Development Council

Find TVU Networks at Broadcast India 2019

UAE and UNESCO Renew Partnership, Extending Efforts to Restore Historic Churches in Mosul

Over 70,000 Visitors, SR2m Falcon Sales on First Day of Riyadh Exhibition

The First Huion Tablet of Inspiroy Dial Series, Q620M was Unveiled at Hong Kong Electronics Fair

ZEISS showcases next-level eye care digitalization at AAO 2019

On Your Marks: 2019 Xi'an Yango International Marathon Starts 20 October

Autodesk Fusion 360 Tools Enable Social Hardware to Advance Design of Prosthetics

Bionik Gold Knee- A New Lease of Life for Young Arthritis Patients

Joy Forum19 to boost Saudi entertainment sector

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
SC likely to wrap up Ayodhya case hearin...
Telangana HC directs state govt, TSRTC e...
Video of 'drug party' inside Jodhpur jai...
Uttar Pradesh: Home Guard Minister assur...
Second PMC Bank depositor dies of heart ...
RSS to convene meeting of Pracharaks in ...
More...    
 
 Top Stories
US, Italy condemn deadly airstrike ... 
Second PMC Bank depositor dies of h... 
Will not be having a vote at this t... 
Uttar Pradesh: Home Guard Minister ... 
Will not be having a vote at this t... 
Qatar defends Turkey's incursion in... 
Banerjee's achievement bigger and t... 
Imperative now is to end incursion ...